Komori
Nihon Kagaku Sangyo (4094) · FactAdvanced

Continued investment in research and development

First written in FY2017-Q1. 20 of 35 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2026.

35entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2018-Q3 – FY2019-Q3AdvancedFY2020-Q3 – FY2022-Q3OtherFY2023-Q1 – FY2024AdvancedFY2025-H1 – FY20262016: 220162017: 420172018: 420182019: 420192020: 420202021: 420212022: 320222023: 420232024: 320242025: 220252026: 12026
Same theme, other companies
Continuation of Company-wide R&D Activities and Resource InvestmentA theme 206 companies write about · 0 as a headwind · 219 as a tailwind

58 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 221 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「R&D expenses for the current consolidated fiscal year were ¥598 million (¥509 million in the Chemicals business and ¥89 million in the Building Materials business).」

    Full-year R&D expenses were ¥598 million, up from ¥511 million in the previous fiscal year.
  2. FY2026-H1AdvancedAnnual report

    「Total R&D expenses for the interim consolidated accounting period were ¥286 million.」

    Interim-period R&D expenses were ¥286 million, up from ¥242 million in the same period of the previous year.
  3. FY2025AdvancedAnnual report

    「R&D expenses for the current consolidated fiscal year were ¥511 million (¥435 million in the Chemicals business and ¥76 million in the Building Materials business).」

    Full-year R&D expenses were ¥511 million, up from ¥453 million in the previous fiscal year.
  4. FY2025-H1AdvancedAnnual report

    「Total R&D expenses for the current interim consolidated accounting period were ¥242 million.」

    Interim-period R&D expenses were ¥242 million, up from ¥214 million in the same period of the previous year.
  5. FY2024Decrease in R&D expensesAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥453 million (¥381 million for the Chemicals business and ¥72 million for the Building Materials business).」

    Full-year research and development expenses were ¥453 million, down from ¥530 million in the previous fiscal year.
  6. FY2024-Q3Decrease in R&D expensesAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥332 million.」

    Research and development expenses were ¥332 million, down from ¥401 million in the same period of the previous year.
  7. FY2024-Q2Decrease in R&D expensesAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥214 million.」

    Research and development expenses were ¥214 million, down from ¥257 million in the same period of the previous year.
  8. FY2024-Q1Decrease in R&D expensesAnnual report

    「Total research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥102 million.」

    Research and development expenses were ¥102 million, down from ¥168 million in the same period of the previous year.
  9. FY2023Decrease in R&D expensesAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥530 million (¥470 million for the Chemicals business and ¥60 million for the Building Materials business).」

    Full-year research and development expenses were ¥530 million, down from ¥602 million in the previous fiscal year. The breakdown was ¥470 million for the Chemicals business and ¥60 million for the Building Materials business.
  10. FY2023-Q3Decrease in R&D expensesAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥401 million.」

    Research and development expenses were ¥401 million, down ¥54 million from ¥455 million in the same period of the previous year.
  11. FY2023-Q2Decrease in R&D expensesAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥257 million.」

    Research and development expenses for the cumulative second quarter were ¥257 million, down ¥54 million from ¥311 million in the same period of the previous year.
  12. FY2023-Q1Decrease in R&D expensesAnnual report

    「Total research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥129 million.」

    Research and development expenses were ¥129 million, down from ¥168 million in the same period of the previous year.
  13. FY2022-Q3AdvancedAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥455 million.」

    Research and development expenses for the cumulative third quarter were ¥455 million, up from ¥353 million in the same period of the previous year.
  14. FY2022-Q2AdvancedAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥311 million.」

    Research and development expenses for the cumulative second quarter were ¥311 million, up from ¥233 million in the same period of the previous year.
  15. FY2022-Q1AdvancedAnnual report

    「The total R&D expenses for the three-month cumulative consolidated period were ¥168 million.」

    Research and development expenses for the cumulative first quarter were ¥168 million, up from ¥106 million in the same period of the previous year.
  16. FY2021AdvancedAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥476 million (¥404 million for the Chemicals business and ¥72 million for the Building Materials business).」

    Full-year research and development expenses were ¥476 million, up from ¥466 million in the previous fiscal year.
  17. FY2021-Q3AdvancedAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥353 million.」

    Research and development expenses increased from ¥233 million for the cumulative second quarter to ¥353 million for the cumulative third quarter, exceeding the ¥323 million recorded in the same period of the previous year.
  18. FY2021-Q2AdvancedAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥233 million.」

    Research and development expenses for the cumulative second quarter were ¥233 million, up from ¥214 million in the same period of the previous year.
  19. FY2021-Q1AdvancedAnnual report

    「Total research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥112 million.」

    Research and development expenses for the cumulative first quarter were ¥112 million, up from ¥106 million in the same period of the previous year.
  20. FY2020AdvancedAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥466 million (¥400 million for the Chemicals business and ¥66 million for the Building Materials business).」

    Full-year research and development expenses were ¥466 million, up from ¥422 million in the previous fiscal year. The breakdown was ¥400 million for the Chemicals business and ¥66 million for the Building Materials business.
  21. FY2020-Q3AdvancedAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥343 million.」

    Research and development expenses for the cumulative third quarter were ¥343 million, up from ¥323 million in the same period of the previous year.
  22. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥214 million.」

    Research and development expenses for the cumulative second quarter were ¥214 million, maintaining research and development investment at the same level as in the same period of the previous year.
  23. FY2020-Q1Slight decline in R&D expensesAnnual report

    「Total research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥106 million.」

    Research and development expenses for the cumulative first quarter were ¥106 million, down ¥8 million from ¥114 million in the same period of the previous year.
  24. FY2019Slight decline in R&D expensesAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥422 million (¥342 million for the Chemicals business and ¥79 million for the Building Materials business).」

    Full-year research and development expenses were ¥422 million, down ¥4 million from ¥426 million in the previous fiscal year.
  25. FY2019-Q3AdvancedAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥313 million.」

    Research and development expenses for the cumulative third quarter were ¥313 million, down from ¥323 million in the same period of the previous year but up from ¥217 million for the cumulative second quarter of the current fiscal year.
  26. FY2019-Q2AdvancedAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥217 million.」

    Research and development expenses for the cumulative second quarter were ¥217 million, up from ¥214 million in the same period of the previous year.
  27. FY2019-Q1AdvancedAnnual report

    「Total research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥114 million.」

    Research and development expenses for the cumulative first quarter were ¥114 million, up from ¥109 million in the same period of the previous year.
  28. FY2018AdvancedAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥426 million (¥356 million for the Chemicals business and ¥70 million for the Building Materials business).」

    Full-year research and development expenses were ¥426 million, up from ¥423 million in the previous fiscal year.
  29. FY2018-Q3AdvancedAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥323 million.」

    Research and development expenses increased from ¥214 million for the cumulative second quarter to ¥323 million for the cumulative third quarter.
  30. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥214 million.」

    The Group incurred ¥214 million in research and development expenses for the cumulative second quarter.
  31. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the consolidated cumulative period were ¥109 million.」

    The Group incurred ¥109 million in research and development expenses for the cumulative first quarter.
  32. FY2017AdvancedAnnual report

    「Research and development expenses for the consolidated fiscal year, including the activity expenses of the teams noted above, were ¥423 million (¥343 million for the Chemicals business and ¥80 million for the Building Materials business).」

    Full-year research and development expenses were ¥423 million, up from ¥320 million for the cumulative third quarter.
  33. FY2017-Q3AdvancedAnnual report

    「Total research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥320 million.」

    Research and development expenses increased from ¥210 million for the cumulative second quarter to ¥320 million for the cumulative third quarter.
  34. FY2017-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥210 million.」

    The Group incurred ¥210 million in research and development expenses for the cumulative second quarter.
  35. FY2017-Q1First statedAnnual report

    「Total research and development expenses for the first quarter of the consolidated cumulative period were ¥109 million.」

    Research and development expenses of ¥109 million were disclosed for the first quarter of the consolidated cumulative period.
Moved together

"Increase in Cash and Cash Equivalents Supported by Cash Generated from Operating Activities" moved the same way as this thread, in the same document, in 14 of its 35 moves.

14129988★123456
  1. ★This thread
  2. 1Increase in Cash and Cash Equivalents Supported by Cash Generated from Operating Activities14×
  3. 2Higher Operating and Ordinary Profit, Primarily Due to Lower Costs12×
  4. 3Full-Scale Operation and Increased Production of Contract Processing for Secondary-Battery Cathode Materials at the Fukushima No. 1 Plant9×
  5. 4Payment of Year-End Dividends9×
  6. 5Sharing Profits and Risks with Shareholders through a Performance-Linked Stock Compensation Plan8×
  7. 6Decrease in Investments and Other Assets and Valuation Difference Due to Falling Share Prices8×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Nihon Kagaku Sangyo's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.